360biolabs, a BioAgilytix company, announced the opening of a new Australian laboratory in Sydney, expanding its national footprint to four laboratories across Australia’s east coast. The new 360biolabs facility in North Ryde is strategically located within one of Sydney’s vibrant science and medtech hubs, Macquarie Park Innovation District alongside a growing community of innovative companies and research organisations. Purpose-designed to support both current and future requirements, the facility features state-of-the-art laboratory and office spaces constructed to exacting standards. The laboratories incorporate robust quality and operational systems for containment, security, IT infrastructure, and reliable service delivery. “The Sydney laboratory marks the next stage of growth for 360biolabs in Australia,” said Alistair Draffan, President.“New South Wales has a strong and growing clinical research sector, and establishing a permanent presence in Sydney allows us to invest alongside that growth. It expands our ability to support clients locally, strengthens our national business and creates a stronger foundation for continued growth in the region.” The Sydney facility has recently achieved Australia’s National Association of Testing Authorities (NATA) for compliance with ISO/IEC 17025 and operates under the same rigorous procedures, policies and quality standards as 360biolabs’ three other world-class facilities, strategically located across the major population and clinical research centres of Australia. “Across 360biolabs, each of our laboratories has assay development capability, supported by the expertise and collaboration of our broader scientific network. Our Sydney team members have worked with 360biolabs for several years, bringing assay development and validation expertise and a shared scientific culture. This supports continuity from development through to sample analysis, with our scientists and instrumentation aligned to deliver reliable results for our clients.”- Melinda Pryor, Executive Vice President, Scientific Operations The Sydney laboratory encompasses significant BSL-2 space supporting PMBC isolation and flow cytometry with separate dedicated laboratories for sample reception, sample storage, in a 24/7 temperature monitored facility, including ULT freezer and vapor phase nitrogen cryostorage. These capabilities support time-sensitive clinical samples where proximity, processing speed and scientific oversight are critical. 360biolabs’ strategic expansion reflects its bench-to-bedside philosophy, placing scientific expertise within established research and clinical precincts to support collaboration between academia, industry and clinicians. In 2024, the company expanded its Melbourne headquarters into a purpose-built 3,000 sqm facility, complementing its dedicated BSL-3 and central laboratory facilities at the Burnet Institute within The Alfred hospital precinct. In Brisbane, 360biolabs operates a laboratory at the Translational Research Institute Australia (TRI), within the Princess Alexandra Hospital precinct. These investments reflect 360biolabs’ continued growth since 2015 and its commitment to strengthening the scientific infrastructure and capabilities supporting clinical research across Australia. 360biolabs, a BioAgilytix company extends its reach beyond Australia. Global sponsors choosing Australia for early-phase clinical development have benefited from assays established at 360biolabs and transferred under quality systems and harmonised SOPs to our USA or European laboratories. Local knowledge, global reach gives sponsors confidence in selecting a bioanalytical partner to take them beyond early phase clinical studies.